Finally, it’s too late for your mother, but older people who have not had the newer two-dose shingles vaccine (Shingrix) ...

Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

Finally, it’s too late for your mother, but older people who have not had the newer two-dose shingles vaccine (Shingrix) should get it, even if they had the old one-dose vaccine (Zostavax ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

Q3 2024 Earnings Call Transcript November 7, 2024Dynavax Technologies Corporation beats earnings expectations.

SEATTLE, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with ...

Good day, ladies and gentlemen, and welcome to the Dynavax Technologies' Third Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded. At the end of the company's ...

-- Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit vaccine -- Ten shingles cases would have been expected ...

(MENAFN- GlobeNewsWire - Nasdaq) -- Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit vaccine -- Ten ...